1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsCaregiver Services Program-Manhattan I is sponsored by New York City Department for the Aging (NYC DFTA). Supports caregivers in Manhattan with individualized information, assistance accessing benefits, counseling, training, support groups, respite care, and supplemental services.
Get alerted about grants like this
Get emailed when new opportunities from “New York City Department for the Aging (NYC DFTA)” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Nonprofit organizations providing caregiver support, case management, academic supports, child care, parenting services, respite care, home attendant services, or homemaking services. Confirm the full requirements in the official notice before applying.
Applications for Caregiver Services Program-Manhattan I are due August 12, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Caregiver Services Program-Manhattan I is funded by New York City Department for the Aging (NYC DFTA). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Three jurisdictions passed laws letting nonprofits get up to 25-50% of grant awards upfront instead of waiting months for reimbursement. The national implications.
Read articleSeven research teams will run the first clinical trials aimed at extending human healthspan under ARPA-H PROSPR contracts worth up to $144M. The milestone-based contract model breaks every convention of federal biomedical funding.
Read articleARPA-H PROSPR program funds seven research teams up to $144M to develop the first clinical trials targeting biological aging itself, testing rapamycin analogs, semaglutide, and retrotransposon inhibitors.
Read article